Alnylam Pharmaceuticals, Inc. · ALNY · FY2025 Q3 · Calendar Q4 2025

Alnylam: AMVUTTRA demand and pipeline progress support raised outlook

The supplied call analysis suggests that accelerating AMVUTTRA adoption and continued pipeline execution support a stronger near-term outlook. The investment case still depends on sustaining launch momentum and converting clinical progress into approvals and broader commercial opportunity.

Reported Before market openNASDAQHealthcare $22.10B market cap
90quality score

Earnings scorecard

Reported versus consensus
Reported EPS $2.90 Consensus $0.56
EPS surprise +416.9% Reported versus consensus
Reported revenue $1.25B Consensus $959.4M
Revenue surprise +30.2% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move -6.7% Event window
SPY move -1.1% Same window
Abnormal move -5.6% Stock minus SPY
Volume 2.2× Versus trailing sessions
Subsequent drift +0.4% Up to 20 sessions
ALNYSPY benchmark

Ask FN2 about ALNY FY2025 Q3

Transcript, numbers and history already loaded
Why did ALNY fall 6.7% after beating EPS estimates in FY2025 Q3?What changed in ALNY's guidance and outlook in FY2025 Q3?Give me the bull and bear case for ALNY after FY2025 Q3 earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Management's reported tone was confident, and the analysis says full-year product-revenue guidance was raised. The call analysis also highlights progress across late-stage programs and planned early-stage trials. A revenue figure in the transcript analysis conflicts with the event scorecard, so this synthesis avoids quoting revenue amounts.

Guidance delta

Raised, according to the supplied call analysis; it describes a higher full-year net product revenue outlook.

Key takeaways

  • The call analysis identifies AMVUTTRA adoption, including first-line and switcher demand, as a central growth driver.
  • The analysis describes supportive U.S. payer feedback and continued geographic expansion, while European pricing and reimbursement remain unresolved.
  • Pipeline execution spans Phase III programs and planned earlier-stage studies; clinical, regulatory and launch outcomes remain uncertain.

Management priorities

  • Continue AMVUTTRA adoption and planned geographic rollout.
  • Advance ZENITH and TRITON clinical programs.
  • Initiate or progress the planned nucresiran, mivelsiran, ALN-6400 and ALN-5288 studies.

Follow ALNY with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
ALNY EPS earnings history estimate and actual scatter chart 10 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $-1.20 Q4 '23 actual $-1.10, beat Q1 '24 estimate $-1.12 Q1 '24 actual $-0.16, beat Q2 '24 estimate $-1.07 Q2 '24 actual $0.56, beat Q3 '24 estimate $-0.92 Q3 '24 actual $-0.50, beat Q2 '25 estimate $-0.54 Q2 '25 actual $0.32, beat Q3 '25 estimate $0.56 Q3 '25 actual $2.90, beat Q4 '25 estimate $1.16 Q4 '25 actual $0.82, miss Q1 '26 estimate $0.87 Q1 '26 actual $1.51, beat Q2 '26 estimate $1.63 Q2 '26 actual $1.21, miss Q3 '26 estimate $1.66 Q3 '26 actual $16.26, beat Q4 '26 estimate $1.75 Q1 '27 estimate $1.78 Q2 '27 estimate $1.77 Q3 '27 estimate $1.99
Show less

Analyst Consensus ?

ConsensusBuy52 ratings
Bullish3873.1%
Neutral1325.0%
Bearish11.9%

Analyst 52W Price Targets

$157.45Current
$96Low
$341.04Average
$570High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 2, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Wells Fargo Equal Weight Equal WeightMaintainOct 30, 2026
UBS Buy BuyMaintainOct 30, 2026
TD Cowen Buy BuyMaintainOct 30, 2026
RBC Capital Outperform OutperformMaintainOct 30, 2026
Raymond James Outperform Strong BuyDowngradeOct 30, 2026
Show 47 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $157.45. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
UBSJoon Lee$329$169.42 +109.0%Oct 30, 2026
BMO CapitalDavid Lebowitz$290$174 +84.2%Oct 30, 2026
Wells FargoAnalyst unavailable$287$174 +82.3%Oct 30, 2026
Raymond JamesMartin Auster$315$174 +100.1%Oct 30, 2026
Stifel NicolausPaul Matteis$225$177.48 +42.9%Oct 29, 2026
See 90 more

Track every rating change on ALNY the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline.…

Historical context

All ALNY earnings
-25.1%FY2026 Q3 · Calendar Q4 2026-28.3%FY2026 Q2 · Calendar Q3 2026+2.8%FY2026 Q1 · Calendar Q2 2026

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
AZN AstraZeneca PLC FY2026 Q3 · Calendar Q4 2026 +7.3% +7.0% AstraZeneca pairs solid growth with pipeline investment and restructuring
BTSG BrightSpring Health Services, Inc. Common Stock FY2026 Q3 · Calendar Q4 2026 +14.2% +11.1% BrightSpring posts strong Q3 growth while maintaining guidance
ABBV AbbVie Inc. FY2026 Q3 · Calendar Q4 2026 +2.4% +1.4% AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth
BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit FY2026 Q3 · Calendar Q4 2026 +14.2% +10.0% BrightSpring posts strong Q3 growth as pharmacy leads
REGN Regeneron Pharmaceuticals, Inc. FY2026 Q3 · Calendar Q4 2026 +21.6% +13.3% Regeneron posts strong Q3 growth as pipeline expands
EXEL Exelixis, Inc. FY2026 Q3 · Calendar Q4 2026 +6.0% +4.8% Exelixis highlights zanzalintinib pipeline after strong Q3

Latest beats and misses

Who reports next

Beat on EPS

Missed on EPS

Get the ALNY recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-11-02T14:00:52.733513+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-02T14:00:52.730549+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-11-02. For educational purposes only; not investment advice.